Johnson & Johnson Earnings Point to New 52-Week High

Health and Healthcare

Published: April 15, 2014 8:30 am

Last Updated: April 28, 2020 12:19 am

Johnson & Johnson (NYSE: JNJ) reported first-quarter results before markets opened Tuesday. The health care giant reported quarterly adjusted diluted earnings per share (EPS) of $1.54 on revenue of $18.1 billion. In the same period a year ago, J&J reported EPS of $1.44 on revenue of $17.5 billion. First-quarter results also compare to the consensus estimates for EPS of $1.48 on revenue of $18.0 billion.

The company’s adjusted earnings excluded $300 million for a one-time tax benefit, partially offset by other charges. Adjusted net profit totaled $4.4 billion, up 7.8% year-over-year for the quarter.

J&J boosted its earnings guidance for the full year from an adjusted EPS range of $5.75 to $5.85 to a new range of $5.80 to $5.90. The consensus estimate had called for EPS of $5.83 on revenues of $74.22 billion.

The firm’s CEO said:

Johnson & Johnson delivered strong first-quarter results driven by successful new product launches and the continued growth of key products. … We also advanced our near-term priorities and long-term growth drivers, positioning us well to deliver sustainable results.

Worldwide consumer sales dropped 3.2% year over year to $3.6 billion, including a negative currency impact of 2.6%. Pharmaceutical sales rose 10.8% to $7.5 billion. Medical devices and diagnostics sales were flat at $7.1 billion. The negative currency exchange impact on total revenues was 1.8% in the quarter.

Primary contributors to the jump in pharmaceutical sales were the company’s psoriasis treatment, an antipsychotic for schizophrenia treatment, a treatment for HIV and new products, including its hepatitis C drug.

J&J has been one of the best performing stocks in the Dow Jones Industrials so far this year, up about 6%. Only drug maker Merck & Co. (NYSE: MRK) and heavy equipment maker Caterpillar Inc. (NYSE: CAT), up 11% and 13% respectively, are performing better. The DJIA is down about 2.3% year to date.

Shares traded about 2.2% higher in the premarket Tuesday, at $99.25 in a 52-week range of $82.07 to $99.38. Thomson Reuters had a consensus analyst price target of around $101.10 before the results were announced.

It’s Your Money, Your Future—Own It (sponsor)

Retirement can be daunting, but it doesn’t need to be.

Imagine having an expert in your corner to help you with your financial goals. Someone to help you determine if you’re ahead, behind, or right on track. With SmartAsset, that’s not just a dream—it’s reality. This free tool connects you with pre-screened financial advisors who work in your best interests. It’s quick, it’s easy, so take the leap today and start planning smarter!

Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality.